Quick Answer
ELITE PHARMACEUTICALS INC /NV/ reported Net Income Loss of -$4.31 million for the year ending 2025.
- ELITE PHARMACEUTICALS INC /NV/ showed a decrease of -121.5% in Net Income Loss from 2024 to 2025.
- This data is from ELITE PHARMACEUTICALS INC /NV/'s annual report (Form 10-K), filed with the SEC on June 30, 2025.
- XBRL data for this metric is available from 2011 to 2025 (15 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 15 years of available data (2011 to 2025), ELITE PHARMACEUTICALS INC /NV/'s Net Income Loss has grown by 68.2%.
- Historical annual values: Fiscal year 2025: -$4.31 million | Fiscal year 2024: $20.11 million | Fiscal year 2023: $3.56 million | Fiscal year 2022: $8.90 million | Fiscal year 2021: $5.09 million | Fiscal year 2020: -$2.24 million | Fiscal year 2019: -$9.28 million | Fiscal year 2018: -$3.67 million | Fiscal year 2017: $3.81 million | Fiscal year 2016: -$683.0 thousand | Fiscal year 2015: $5.22 million | Fiscal year 2014: -$41.26 million | Fiscal year 2013: $1.49 million | Fiscal year 2012: -$15.06 million | Fiscal year 2011: -$13.58 million.
- Data sourced from SEC EDGAR public filings as of June 22, 2026.
Last verified: